chiron

At chiron we know the importance of standardization. That is why we are actively participating in the standardization of organ-on-chips and organoids!

We are pleased to share a new update from the OPZuid-supported INTELLECTUALS project, where our consortium is developing a high-throughput 3D cartilage-on-a-chip platform for osteoarthritis research. During the latest reporting period, the project made strong progress across manufacturing, quality control, biological validation, and hydrogel integration. A major milestone was the manufacturing and testing of cells and hydrogel injection. The consortium also continued to advance: • scalable manufacturing and alternative material processing • quality-management documentation and SOP development • sterilization, packaging, and labelling activities • validation with patient-derived chondrocytes • hydrogel formulation and integration into the chip platform The project’s results have also been presented at international conferences, helping to raise awareness of the potential of organ-on-chip technologies to improve osteoarthritis research and drug development. This progress is the result of close collaboration between chiron, University of Twente, Maastricht University, TNO, Medace BV, and Hy2Care® BV. We look forward to the next phase: expanding production qualification, continuing biological validation, and further demonstrating the platform’s potential for more predictive and human-relevant osteoarthritis research. We would like to thank STIMULUS and all the other funding bodies that are currently supporting this project! #OPZuid #INTELLECTUALS #OrganOnChip #CartilageOnChip #Osteoarthritis #Biotechnology #MedTech #DrugDevelopment #Innovation #Collaboration

Another important milestone for chiron! Sensors and organ-on-chip (or advanced in-vitro models) will be the gold standard of pre-clinical research! By joining forces with scientists/researchers across Europe we plan to create disruptive technologies that can bring new therapies to market in a shorter and more reliable way!

Some of the companies at BIO this week won’t survive the next five years. After four days on the floor, it wasn’t difficult to see which ones are positioning themselves to thrive and which ones are not. This was the best BIO International Convention I’ve attended in close to a decade. Roughly 22,000 people. A packed exhibit hall every afternoon. The industry is back. The energy was real, and people were there to build partnerships and make deals. But one of the most significant technologies changing the industry was AI. Not on the edges. Front and center, with an entire section of the exhibit hall dedicated to AI companies. And the progress is real, across discovery, data generation, interpretation, prediction, imaging, and operational intelligence. Nearly every part of drug development is being reshaped. Here’s what was obvious on the floor. The organizations that embrace these technologies will become more productive, scale faster, and operate with greater precision and lower risk. Those that hesitate will find it increasingly difficult to compete. The second major shift was equally significant: NAMs. Advanced 3D in vitro systems are changing how we generate evidence before and alongside clinical trials. Higher quality human-relevant data leads to more informed development decisions. Combine AI with these technologies, and the opportunity is substantial: faster learning cycles, more informed decisions, and ultimately medicines that are more effective and less toxic. That future felt tangible at BIO this week. It was also great catching up with Dustin Dopsa and Carlo Alberto Paggi, PhD from chiron. The science throughout the conference was extraordinary. The companies that win won’t simply have the best science. They’ll be built to move at the speed modern science now demands. The next competitive advantage in biotech won’t be the science alone. It will be an organization’s ability to translate science into business decisions faster than everyone else.

We're in San Diego for work. WE SWEAR! Don't believe us? Drop by the Health Holland booth at the BIO International Convention to say hello! We've got lots to talk about: human-relevant data for de-risking clinical trials, a portfolio of applications in #oncology, #arthritis, and always building more, Jason Derulo, the gorgeous weather in San Diego, last night's San Diego Padres win against the Braves... whatever your fancy, we've got you covered! #BIO #NL #NAMs #seeThingsDifferently

This year has already been full of adventures and activities! From the beautiful beaches in Goa (India) to the incredible lights of Shanghai (China), chiron is exploring possibilities world wide! But is not only about chiron! This post is specific for the people attending the ARI Orthopaedics Conferences in Davos! Here, our collaborators will be presenting data obtained using chiron’s technologies!   From the presentation of Tim Welting (Exploring the bioactivity of synovial fluid in osteoarthritis as a vector for intra-joint biomolecular cross-talk) to the posters of Laura Mecchi (A Cartilage-on-Chip Platform for Human MSC Mechanobiology) and Zahra Sarmadian (Synergistic Effects of Mechanical Loading and Inflammation on Chondrocyte Gene Expression in a Cartilage-on-Chip Model) there is going to be a lot of interesting scientific discoveries! We would like to wish all the participants a wonderful event and if you are interested in the platforms here is the link: https://www.chrn.co/ #mechanical #stimulation #science #future #technology #standard #NAMs #Robust #Reproducible #Human #Relevant

WARNING: this post was NOT generated with AI. It may evoke real thoughts and emotions! Before Carlo Alberto Paggi, PhD and Dustin Dopsa embarked on the journey we call, chiron, both of them worked at big-name corporate companies. The things they learned during those phases of their career were, and are, absolutely essential for how we go about tackling challenges, creating solutions, and developing products at chiron, only a daily basis. It’s ALL about the end user.  Regardless if it’s a service we provide, or a piece of technology that lands in the hands of the user, the real question is: “are we doing something that actually benefits our customers?”. We approached μMass™ in the same manner. We built a foundational platform, upon which we have now developed various human-biology applications, to answer the questions of pharma drug-development teams. In every step of the way, we ensured that the product and corresponding portfolio of services we were creating, would have a strategic impact on those same drug-development teams. If this speaks to you, and you haven’t been in touch with us yet, please reach out. We’d be very happy to meet you, and hear more about what you’re working on. #microMass #humanRelevantData  #3DCellCulture #customerIsKing

A tumour isn't a clump of cells, it's a fortress! WITH WALLS! And guess what? Most lab models pretend the walls aren't there. The clip below is an extended cut from the µMass™ video we launched back in April. In it, our Co-founder Carlo Alberto Paggi, PhD points to a problem cell-therapy developers know well: a solid tumour is wrapped in a dense barrier of cells a therapy has to break through before it can work; a flat 2D culture simply can't show you that. So, the data you'd base a decision on doesn't reflect the disease. Solving real-world problems like the one mentioned above, for the pharmaceutical industry, is why chiron exists. We're not coming up with clever technologies in search of an industry to adopt it—it's exactly the reverse. The problems we build for are ones our own founders and scientists ran into inside pharma and biotech. We know the questions drug developers actually need answered, and the standard of evidence it takes to answer them. µMass™ is one of the ways we answer those questions: a platform, with applications built on top of it, enabling human-relevant, 3D aggregate data, reproducible and traceable enough to support real development decisions in solid-tumour oncology, arthritis, liver, and beyond. chiron is industry, for the industry; and for those, who see things differently. #pharma #cellTherapy #oncology #spheroids #microMass

This is massive progress! Very exciting stuff.